Fármacos Inhibidores Selectivos de La Ciclooxigenasa-2

8/18/2019 Fármacos Inhibidores Selectivos de La Ciclooxigenasa-2

1/13

FÁRMACOS INHIBIDORES SEL

DE LA CICLOOXIGENASA-2

EQUIPO #3:VÍCTOR SANTANA REYES 12!!ALBA MARIANA GU"MÁN RASCN 12$%$&MARIANA ELIAN NARVAE" GUTIERRE" 12!3!ANA VALERIA PONCE RODRÍGUE" 12$%'OMAR IVAN SOLTERO FERNANDE" 1%$!!

-

TERAP(UTICAGRUPO


2/13

COX 2

• P+,,./0 +,0456. 04,.7,./, 89+ 45/945.0 ,59.,

E 0 8+5.4580


3/13

Á4579 [email protected]

L58995,.00 C54995,.00

COX-2

B9@,0 =,40.5=90 5.?0=0456. +,740 0 +,8,/0

5.?0=0/9+50 799+9

COX-1

E


4/13

INHIBIDORES DE COX 2>

• A4459., 0./585+/540 0./55.?0=0/9+50 ; 0.0540

• R5,9 ♥.

• FDA exigió actualización de etiquetas.

•Fármaco representativo celecoxib.


5/13

CELECOXIB

• A./55.?0=0/9+59 .9 ,/,+957,9 AINES>

• P,+/,.,45,./, 0 +89 7, 5.5579+, ,,4/59

0 454995,.00-2 C95>

• I.7540459.,: A559 5./9=J/549 ,. , /+0/0=5,.

0+/+95 0+/+5/5 +,=0/957, ; ,89.755/5

0.@590./,>


6/13

•C9./+05.7540459.,:

• H58,+,.555707>

• U4,+0456. 88/540 04/50 9 ,=9++050 0/+95./• E=0+0K9>

• L04/0.450>

• D5


7/13

• A7=5.5/+0456. 0 9+0:

• D95 =J>: &%% =70 80+0 /970 0 5.754045

I>H> =97,+070 ,/0,4570 5.5450+ 49. 795+,49=,.7070> N9 5.754079 ,. .59>

Artrosis y

espondilitisanquilosante

200 mg/24 h ó 10

mg/12 h.

Artritis reumatoide 100 mg/12 h*

//8:>07,=,4=>,4,,495-=%10%1


8/13

VALDECOXIB

• A./55.?0=0/9+59 .9 ,/,+957,9>

• S,,4/59 7, 0 COX 2>

• A.0549 A./55.?0=0/9+59 A./585+/549>

• I.7540459.,:

D99+ 079 D5=,.9++,08+5=0+50A+/+90+/+5

+,=0

D99+89/98,+0/9+

59

R,74456.7, 9

+,@,+5=5,./

9 7,985J4,9


9/13

•C9./+05.7540459.,:• H58,+,.555707 0 07,495 ;9 • H5/9+50 7, 0=0 9 +,04459., 0+540 0 AIN• E=0+0K9 ; 04/0.450>• I>H> +0,>• E. I.?0=0/9+50 5./,/5.0>• ICC>• D99+ 89/98,+0/9+59 /+0 ;80 49+9.0+59>• C0+75980/0 5@=540 9 ,. C,+,+9040+

,/0,4570>


10/13

•A+/+95 9 0+/+5/5 +,=0/957,• 1%= 70 =J>> 2% =

• ! 09 ; !% I>H> =97,+070: 1%= 7

•D5=,.9++,0 8+5=0+50:• &%= 70 0 7,=0.70> • I>H> =97,+070: 2% = 70

M9+079 P+,K P+,K-B/0=0./,

T9++, 2%%!


11/13

PARECOXIB SDICO

• E , W.549 AINE ,,4/59 7, 0 COX-2 07=5.5/+079 =

5.;,4459.,> V0 5./+0=40+>

• P,+5979 8,+598,+0/9+59 799+ 079>

• A9+456.: 1! =5.>

• FJ+=049 04/59: 07,495>

• E4+,456. +,.0>


12/13

•E


13/13

REFERENCIAS BIBLIOGRÁFICAS:• G997=0. G5=0.> 2%12> B0, F0+=0496540 7, 0 T,+08/5

M4 G+0 H5> PJ> 1%1'-1%1

• FDA> D545,=+, 2%%%> P0+,495 S975=> =,7540 OZ4,+ R,5,%3! NDA 21-2$&> E.,+9 2%1 D, P0+,495 E,4/5, S==0+; B

70/9>

• //8:>07,=,4=>,8+5.45859-04/59-4,,495-=%10%1

• M9+079 I> P,+,K A> P,+,K-B/0=0./, F> T9++, L> 2%%!> G

=0.,9 45.549 7, 0 0+/+95 7, 407,+0 ; +9750 > Revista de la SocEspañola del Dolor 2$-3%2>

• F+,+ C> P0/; B> F5/KG,+07 G> 2%%!> P0+,495 V07,49

C0+759040+ R5> Circulation 2&$> 9.5.,: //8

:45+4>009+.0>9+49./,./11132&$>9+/ #

• //8:>07,=,4=>,8+5.45859-04/59-07,495-=%10%3
http://www.vademecum.es/principios-activos-celecoxib-m01ah01http://www.vademecum.es/principios-activos-celecoxib-m01ah01http://circ.ahajournals.org/content/111/3/249.shorthttp://circ.ahajournals.org/content/111/3/249.shorthttp://circ.ahajournals.org/content/111/3/249.shorthttp://circ.ahajournals.org/content/111/3/249.shorthttp://circ.ahajournals.org/content/111/3/249.shorthttp://www.vademecum.es/principios-activos-celecoxib-m01ah01http://www.vademecum.es/principios-activos-celecoxib-m01ah01http://www.vademecum.es/principios-activos-celecoxib-m01ah01

Fármacos Inhibidores Selectivos de La Ciclooxigenasa-2

Documents

Transcript of Fármacos Inhibidores Selectivos de La Ciclooxigenasa-2